GPR35
GPR35 is a Class A, rhodopsin-like G protein-coupled receptor which is predominantly expressed in immune and gastrointestinal tissue, with notable expression in the ileum (rat and human GPR35), the spleen (rat and murine GPR35) and the pancreas (human GPR35).
GPR35 Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 0223 | Kynurenic acid |
| Endogenous GPR35 ligand; also broad spectrum glutamatergic antagonist | |
| 3694 | Kynurenic acid sodium salt |
| Sodium salt of kynurenic acid (Cat. No. 0223) | |
| 0593 | NPPB |
| Putative GPR35 agonist | |
| 4879 | TC-G 1001 |
| GPR35 agonist; more potent than zaprinast (Cat. No. 0947) | |
| 4457 | YE 120 |
| GPR35 agonist | |
| 0947 | Zaprinast |
| GPR35 agonist | |
GPR35 Antagonists |
|
| Cat. No. | Product Name / Activity |
| 4293 | CID 2745687 |
| GPR35 antagonist | |
| 4172 | ML 145 |
| GPR35 antagonist | |
GPR35 is a Class A, rhodopsin-like G protein-coupled receptor which is predominantly expressed in immune and gastrointestinal tissue, with notable expression in the ileum (rat and human GPR35), the spleen (rat and murine GPR35) and the pancreas (human GPR35). Despite being first identified in 1998, the receptor is relatively poorly characterized and until recently was regarded as an orphan receptor. More recent work has identified kynurenic acid and lysophosphatidic acid as potential endogenous ligands for GPR35, and has also demonstrated that GPR35 functions as a receptor for T3 and reverse T3 thyroid hormones, rosmarinic acid, and 3-nitrotyrosine.
Small nucleotide polymorphisms (SNPs) within GPR35 have been linked to cardiovascular disease, and GPR35 signaling is also thought to be involved in inflammation, nociception, and glucose metabolism. In addition. GPR35 has been reported as a potential oncogene in gastric cancer, and its tyrosine metabolite binding capability identifies GPR35 as a potential target for diseases associated with abnormal tyrosine metabolism.